FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Core Viewpoint - Omeros Corporation has received FDA approval for YARTEMLEA® (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), marking it as the first and only approved lectin pathway inhibitor [1] Group 1: Product Approval - The FDA has approved YARTEMLEA for the treatment of TA-TMA, a serious complication associated with stem-cell transplantation [1] - YARTEMLEA functions by selectively inhibiting MASP-2, which is involved in the activation of the lectin pathway of complement [1] Group 2: Market Implications - The approval of YARTEMLEA positions Omeros Corporation uniquely in the market as the sole provider of a lectin pathway inhibitor [1]